Table 5. Predictive performance for identifying PD-L1 negative and positive NSCLC.
| Parameters | AUC (95% CI) | P value | Cutoff | Sensitivity, % | Specificity, % | Comparison with a combined diagnosis |
|---|---|---|---|---|---|---|
| ADC (×10−3 mm2/s) | 0.534 (0.416−0.649) | 0.614 | − | − | − | − |
| D (×10−3 mm2/s) | 0.743 (0.630−0.836) | <0.001# | 1.140 | 97.22 | 50.00 | Z=3.688, P<0.001# |
| D* (×10−3 mm2/s) | 0.542 (0.424−0.657) | 0.530 | − | − | − | − |
| f (%) | 0.667 (0.549−0.771) | 0.007# | 36.24 | 88.89 | 42.50 | Z=4.626, P<0.001# |
| MTRasym (3.5 ppm) (%) | 0.766 (0.655−0.856) | <0.001# | 3.570 | 47.22 | 95.00 | Z=3.517, P<0.001# |
| SUVmax (g/cm3) | 0.801 (0.693−0.884) | <0.001# | 5.900 | 88.89 | 60.00 | Z=3.372, P=0.001# |
| MTV (cm3) | 0.741 (0.628−0.835) | <0.001# | 16.57 | 55.56 | 92.50 | Z=3.293, P=0.001# |
| TLG (g) | 0.789 (0.680−0.874) | <0.001# | 71.75 | 58.33 | 85.00 | Z=2.996, P=0.003# |
| Combined diagnosis | 0.946 (0.869−0.985) | <0.001# | − | 86.11 | 92.50 | − |
The combined diagnosis represents MTRasym (3.5 ppm) + D + SUVmax. #, indicates statistically significant differences. PD-L1, programmed cell death-ligand 1; NSCLC, non-small cell lung cancer; ADC, apparent diffusion coefficient; D, diffusion coefficient; D*, pseudo diffusion coefficient; f, perfusion fraction; MTRasym (3.5 ppm), magnetization transfer ratio asymmetry at 3.5 ppm; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis.